Abstract
Following allogeneic hematopoietic cell transplantation (allo-HCT), the gastrointestinal (GI) tract is frequently affected by acute graft-versus-host disease (aGVHD), the pathophysiology of which is associated with a dysbiotic microbiome. Since microbial composition varies along the length of the GI tract, the authors hypothesized that microbiome features correlate with the pattern of organ involvement after allo-HCT. We evaluated 266 allo-HCT recipients from whom 1303 stool samples were profiled by 16S ribosomal gene sequencing. Patients were classified according to which organs were affected by aGVHD. In the 20 days prior to disease onset, GVHD patients had lower abundances of members of the class Clostridia, lower counts of butyrate producers, and lower ratios of strict-to-facultative (S/F) anaerobic bacteria compared with allograft recipients who were free of GVHD. GI GVHD patients showed significant reduction in microbial diversity preonset. Patients with lower GI aGVHD had lower S/F anaerobe ratios compared with those with isolated upper GI aGVHD. In the 20 days after disease onset, dysbiosis was observed only in GVHD patients with GI involvement, particularly those with lower-tract disease. Importantly, Clostridial and butyrate-producer abundance as well as S/F anaerobe ratio were predictors of longer overall survival; higher abundance of butyrate producers and higher S/F anaerobe ratio were associated with decreased risk of GVHD-related death. These findings suggest that the intestinal microbiome can serve as a biomarker for outcomes of allo-HCT patients with GVHD.
Original language | English |
---|---|
Pages (from-to) | 2385-2397 |
Number of pages | 13 |
Journal | Blood |
Volume | 140 |
Issue number | 22 |
DOIs | |
State | Published - 1 Dec 2022 |
Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2022 The American Society of Hematology
Funding
This work was supported in part by the MSK Internal Diversity Enhancement Award (IDEA); National Institutes of Health, National Cancer Institute award numbers R01-CA228358 , R01-CA228308 , P30 CA008748 MSK Cancer Center Core Grant and P01-CA023766 ; National Heart, Lung, and Blood Institute award numbers R01-HL123340 , R01-HL147584 , and K08HL143189 ; National Institute of Aging award number P01-AG052359 ; Starr Cancer Consortium ; and Tri Institutional Stem Cell Initiative . Additional funding was received from the Lymphoma Foundation , The Susan and Peter Solomon Divisional Genomics Program , Cycle for Survival , MSKCC Cancer Systems Immunology Pilot Grant, Empire Clinical Research Investigator Program , the Society for MSK , the Staff Foundation , the American Society for Transplantation and Cellular Therapy, MSKCC Leukemia SPORE Career Enhancement Program , and the Parker Institute for Cancer Immunotherapy .
Funders | Funder number |
---|---|
Society for MSK | |
Staff Foundation | |
Starr Cancer Consortium | |
National Institutes of Health | |
National Institute on Aging | P01-AG052359 |
National Heart, Lung, and Blood Institute | K08HL143189, R01-HL123340, R01-HL147584 |
National Cancer Institute | P01-CA023766, R01-CA228308, P30 CA008748, R01-CA228358 |
Memorial Sloan-Kettering Cancer Center | |
Parker Institute for Cancer Immunotherapy | |
American Society for Transplantation and Cellular Therapy | |
Cycle for Survival |